Document:

exv4w13

EXHIBIT
4.13

ONHEALTH NETWORK COMPANY

AMENDED AND RESTATED

1997 STOCK OPTION PLAN

SECTION 1

DEFINITIONS

     As used herein, the following terms shall have the meanings indicated below:

     (a) “Committee” shall mean a Committee of two or more directors who shall be appointed by and
serve at the pleasure of the Board. As long as the Company’s securities are registered pursuant to
Section 12 of the Securities Exchange Act of 1934, as amended, then, to the extent necessary for
compliance with Rule 16b-3, or any successor provision, each of the members of the Committee shall
be a “Non-Employee Director.” For purposes of this Section 1(a) “Non-Employee Director” shall have
the same meaning as set forth in Rule 16b 3, or any successor provision, as then in effect, of the
General Rules and Regulations under the Securities Exchange Act of 1934, as amended.

     (b) The “Company” shall mean OnHealth Network Company, a Washington corporation.

     (c) “Fair Market Value” shall mean (i) if such stock is reported by the Nasdaq National Market
or Nasdaq SmallCap Market or is listed upon an established stock exchange or exchanges, the
reported closing price of such stock by the Nasdaq National Market or Nasdaq SmallCap Market or on
such stock exchange or exchanges on the date the option is granted or, if no sale of such stock
shall have occurred on that date, on the next preceding day on which there was a sale of stock;
(ii) if such stock is not so reported by the Nasdaq National Market or Nasdaq SmallCap Market or
listed upon an established stock exchange, the average of the closing “bid” and “asked” prices
quoted by the National Quotation Bureau, Inc. (or any comparable reporting service) on the date the
option is granted, or if there are no quoted “bid” and “asked” prices on such date, on the next
preceding date for which there are such quotes; or (iii) if such stock is not publicly traded as of
the date the option is granted, the per share value as determined by the Board, or the Committee,
in its sole discretion by applying principles of valuation with respect to all such options.

     (d) The “Internal Revenue Code” is the Internal Revenue Code of 1986, as amended from time to
time.

     (e) “Option Stock” shall mean Common Stock of the Company (subject to adjustment as described
in Section 12) reserved for options pursuant to this Plan.

     (f) “Non-Employee Director” shall mean members of the Board who are not employees of the
Company or any subsidiary, except as defined in and for Section 1(a).

     (g) The “Optionee” means an employee of the Company or any Subsidiary to whom an incentive
stock option has been granted pursuant to Section 9; a consultant or advisor to or director
(including a Non-Employee Director), employee or officer of the Company or any Subsidiary to whom a
nonqualified stock option has been granted pursuant to Section 10; or a Non-Employee Director to
whom a nonqualified stock option has been granted pursuant to Section 17.

     (h) “Parent” shall mean any corporation which owns, directly or indirectly in an unbroken
chain, fifty percent (50%) or more of the total voting power of the Company’s outstanding stock.

 

 

     (i) The “Plan” means the OnHealth Network Company 1997 Stock Option Plan, as amended by the
1999 Amendment and restated in this Amended and Restated OnHealth Network Company 1997 Stock Option
Plan as such may be further amended hereafter from time to time, including the form of Option
Agreements as they may be modified by the Board from time to time.

     (j) A “Subsidiary” shall mean any corporation of which fifty percent (50%) or more of the
total voting power of outstanding stock is owned, directly or indirectly in an unbroken chain, by
the Company.

     (k) “Non-Employee Director” shall mean members of the Board who are not employees of the
Company or any subsidiary, except as defined in and for Section 1(a).

     (l) “1999 Amendment” means the Amendment increasing the authorized shares reserved for grant
under the Plan from 1,750,000 to 4,750,000 as adopted by the Company’s shareholders at the June 15,
1999 annual meeting.

SECTION 2.

PURPOSE

     The purpose of the Plan is to promote the success of the Company and its Subsidiaries by
facilitating the retention of competent personnel and by furnishing incentive to officers,
directors, employees, consultants, and advisors upon whose efforts the success of the Company and
its Subsidiaries will depend to a large degree.

     It is the intention of the Company to carry out the Plan through the granting of stock options
which will qualify as “incentive stock options” under the provisions of Section 422 of the Internal
Revenue Code, or any successor provision, pursuant to Section 9 of this Plan, and through the
granting of “nonqualified stock options” pursuant to Section 10 and 17 of this Plan.

SECTION 3.

EFFECTIVE DATE OF PLAN

     The Plan was initially effective as of the date of adoption by the Board of Directors, and the
Amendment on June 15, 1999 with approval by the shareholders of the Company.

SECTION 4.

ADMINISTRATION

     The Plan shall be administered by the Board of Directors of the Company (hereinafter referred
to as the “Board”) or by a Committee which may be appointed by the Board from time to time
(collectively referred to as the “Administrator”). The Administrator shall have all of the powers
vested in it under the provisions of the Plan, including but not limited to exclusive authority
(where applicable and within the limitations described in this Plan) to determine, in its sole
discretion, whether an incentive stock option or nonqualified stock option shall be granted, the
individuals to whom, and the time or times at which, options shall be granted, the number of shares
subject to each option and the option price and terms and conditions of each option. The
Administrator shall have full power and authority to administer and interpret the Plan, to make and
amend rules, regulations and guidelines for administering the Plan, to prescribe the form and
conditions of the respective stock option agreements (which may vary from Optionee to Optionee)
evidencing each option and to make all other determinations necessary or advisable for the
administration of the Plan. The Administrator’s interpretation of the Plan, and all actions taken
and determinations made by the Administrator pursuant to the power vested in it hereunder, shall be
conclusive and binding on all parties concerned.

2

 

     No member of the Board or the Committee shall be liable for any action taken or determination
made in good faith in connection with the administration of the Plan. In the event the Board
appoints a Committee as provided hereunder, any action of the Committee with respect to the
administration of the Plan shall be taken pursuant to a majority vote of the Committee members or
pursuant to the written resolution of all Committee members.

SECTION 5.

PARTICIPANTS

     The Administrator shall from time to time, at its discretion and without approval of the
shareholders, designate those employees, officers, directors (including Non-Employee Directors),
consultants, and advisors of the Company or of any Subsidiary to whom nonqualified stock options
shall be granted pursuant to Section 10 of this Plan; provided, however, that consultants or
advisors shall not be eligible to receive stock options hereunder unless such consultant or advisor
renders bona fide services to the Company or Subsidiary and such services are not in connection
with the offer or sale of securities in a capital raising transaction; and, provided further, that
Non-Employee Directors will be granted options pursuant to Section 17 of this Plan without any
further action by the Administrator. The Administrator shall, from time to time, at its discretion
and without approval of the shareholders, designate those employees of the Company or any
Subsidiary to whom incentive stock options shall be granted pursuant to Section 9 of this Plan.
The Administrator may grant additional incentive stock options or nonqualified stock options under
this Plan to some or all participants then holding options or may grant options solely or partially
to new participants. In designating participants, the Administrator shall also determine the
number of shares to be optioned to each such participant. The Board may from time to time
designate individuals as being ineligible to participate in the Plan.

SECTION 6.

STOCK

     The Stock to be optioned under this Plan shall consist of authorized but unissued shares of
Option Stock. Four Million Seven Hundred Fifty Thousand (4,750,000) shares of Option Stock shall
be reserved and available for options under the Plan; provided, however, that the total number of
shares of Option Stock reserved for options under this Plan shall be subject to adjustment as
provided in Section 12 of the Plan. In the event that any outstanding option under the Plan for
any reason expires or is terminated prior to the exercise thereof, the shares of Option Stock
allocable to the unexercised portion of such option shall continue to be reserved for options under
the Plan and may be optioned hereunder.

SECTION 7.

DURATION OF PLAN

     Incentive stock options may be granted pursuant to the Plan from time to time during a period
of ten (10) years from the effective date as defined in Section 3. Nonqualified stock options may
be granted pursuant to the Plan from time to time after the effective date of the Plan and until
the Plan is discontinued or terminated by the Board. Any incentive stock option granted during
such ten-year period and any nonqualified stock option granted prior to the termination of the Plan
by the Board shall remain in full force and effect until the expiration of the option as specified
in the written stock option agreement and shall remain subject to the terms and conditions of this
Plan.

SECTION 8.

PAYMENT

     Optionees may pay for shares upon exercise of options granted pursuant to this Plan with cash,
personal check, certified check or, if approved by the Administrator in its sole discretion, Common
Stock

3

 

of the Company valued at such Stock’s then Fair Market Value, or such other form of payment
as may be authorized by the Administrator. The Administrator may, in its sole discretion, limit
the forms of payment available to the Optionee and may exercise such discretion any time prior to
the termination of the option granted to the Optionee or upon any exercise of the option by the
Optionee.

     With respect to payment in the form of Common Stock of the Company, the Administrator may
require advance approval or adopt such rules as it deems necessary to assure compliance with Rule
16b-3, or any successor provision, as then in effect, of the General Rules and Regulations under
the Securities Exchange Act of 1934, if applicable.

SECTION 9.

TERMS AND CONDITIONS OF INCENTIVE STOCK OPTIONS

     Each incentive stock option granted pursuant to this Section 9 shall be evidenced by a written
stock option agreement (the “Option Agreement”). The Option Agreement shall be in such form as may
be approved from time to time by the Administrator and may vary from Optionee to Optionee;
provided, however, that each Optionee and each Option Agreement shall comply with and be subject to
the following terms and conditions:

     (a) Number of Shares and Option Price. The Option Agreement shall state the total number of
shares covered by the incentive stock option. To the extent required to qualify the Option as an
incentive stock option under Section 422 of the Internal Revenue Code, or any successor provision,
the option price per share shall not be less than one hundred percent (100%) of the Fair Market
Value of the Common Stock per share on the date the Administrator grants the option; provided,
however, that if an Optionee owns stock possessing more than ten percent (10%) of the total
combined voting power of all classes of stock of the Company or of its Parent or any Subsidiary,
the option price per share of an incentive stock option granted to such Optionee shall not be less
than one hundred ten percent (110%) of the Fair Market Value of the Common Stock per share on the
date of the grant of the option. The Administrator shall have full authority and discretion in
establishing the option price and shall be fully protected in so doing.

     (b) Term and Exercisability of Incentive Stock Option. The term during which any incentive
stock option granted under the Plan may be exercised shall be established in each case by the
Administrator. To the extent required to qualify the Option as an incentive stock option under
Section 422 of the Internal Revenue Code, or any successor provision, in no event shall any
incentive stock option be exercisable during a term of more than ten (10) years after the date on
which it is granted; provided, however, that if an Optionee owns stock possessing more than ten
percent (10%) of the total combined voting power of all classes of stock of the Company or of its
parent or any Subsidiary, the incentive stock option granted to such Optionee shall be exercisable
during a term of not more than five (5) years after the date on which it is granted.

          The Option Agreement shall state when the incentive stock option becomes exercisable and shall
also state the maximum term during which the option may be exercised. In the event an incentive
stock option is exercisable immediately, the manner of exercise of the option in the event it is
not exercised in full immediately shall be specified in the Option Agreement. The Administrator
may accelerate the exercisability of any incentive stock option granted hereunder which is not
immediately exercisable as of the date of grant.

     (c) Other Provisions. The Option Agreement authorized under this Section 9 shall contain such
other provisions as the Administrator shall deem advisable. Any such Option Agreement shall
contain such limitations and restrictions upon the exercise of the option as shall be necessary to
ensure that such option will be considered an “incentive stock option” as defined in Section 422 of
the Internal Revenue Code or to conform to any change therein.

4

 

SECTION 10.

TERMS AND CONDITIONS OF NONQUALIFIED STOCK OPTIONS

     Each nonqualified stock option granted pursuant to this Section 10 shall be evidenced by a
written Option Agreement. The Option Agreement shall be in such form as may be approved from time
to time by the Administrator and may vary from Optionee to Optionee; provided, however, that each
Optionee and each Option Agreement shall comply with and be subject to the following terms and
conditions:

     (a) Number of Shares and Option Price. The Option Agreement shall state the total number of
shares covered by the nonqualified stock option. Unless otherwise determined by the Administrator,
the option price per share shall be one hundred percent (100%) of the Fair Market Value of the
Common Stock per share on the date the Administrator grants the option; provided, however, that the
option price may not be less than eighty five percent (85%) of the Fair Market Value of the Common
Stock per share on the date of grant.

     (b) Term and Exercisability of Nonqualified Stock Option. The term during which any
nonqualified stock option granted under the Plan may be exercised shall be established in each case
by the Administrator. The Option Agreement shall state when the nonqualified stock option becomes
exercisable and shall also state the maximum term during which the option may be exercised. In the
event a nonqualified stock option is exercisable immediately, the manner of exercise of the option
in the event it is not exercised in full immediately shall be specified in the stock option
agreement. The Administrator may accelerate the exercisability of any nonqualified stock option
granted hereunder which is not immediately exercisable as of the date of grant.

     (c) Withholding. The Company or its Subsidiary shall be entitled to withhold and deduct from
future wages of the Optionee all legally required amounts necessary to satisfy any and all
withholding and employment-related taxes attributable to the Optionee’s exercise of a nonqualified
stock option. In the event the Optionee is required under the Option Agreement to pay the Company,
or make arrangements satisfactory to the Company respecting payment of, such withholding and
employment-related taxes, the Administrator may, in its discretion and pursuant to such rules as it
may adopt, permit the Optionee to satisfy such obligation, in whole or in part, by electing to have
the Company withhold shares of Common Stock otherwise issuable to the Optionee as a result of the
option’s exercise equal to the amount required to be withheld for tax purposes. Any stock elected
to be withheld shall be valued at its Fair Market Value, as of the date the amount of tax to be
withheld is determined under applicable tax law. The Optionee’s election to have shares withheld
for this purpose shall be made on or before the date the option is exercised or, if later, the date
that the amount of tax to be withheld is determined under applicable tax law. Such election shall
be approved by the Administrator and otherwise comply with such rules as the Administrator may
adopt to assure compliance with Rule 16b-3, or any successor provision, as then in effect, of the
General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

     (d) Other Provisions. The Option Agreement authorized under this Section 10 shall contain
such other provisions as the Administrator shall deem advisable.

SECTION 11.

TRANSFER OF OPTION

     No incentive stock option shall be transferable, in whole or in part, by the Optionee other
than by will or by the laws of descent and distribution and, during the Optionee’s lifetime, the
option may be exercised only by the Optionee. If the Optionee shall attempt any transfer of any
incentive stock option granted under the Plan during the Optionee’s lifetime, such transfer shall
be void and the incentive stock option, to the extent not fully exercised, shall terminate.

     The Administrator may, in its sole discretion, permit the Optionee to transfer any or all
nonqualified stock options to any member of the Optionee’s “immediate family” as such term is
defined in Rule 16a-1(e) promulgated under the Securities Exchange Act of 1934, or any successor
provision, or to

5

 

one or more trusts whose beneficiaries are members of such Optionee’s “immediate
family” or partnerships in which such family members are the only partners; provided, however, that
the Optionee receives no consideration for the transfer and such transferred nonqualified stock
option shall continue to be subject to the same terms and conditions as were applicable to such
nonqualified stock option immediately prior to its transfer.

SECTION 12.

RECAPITALIZATION, SALE, MERGER, EXCHANGE OR LIQUIDATION

     In the event of an increase or decrease in the number of shares of Common Stock resulting from
a subdivision or consolidation of shares or the payment of a stock dividend or any other increase
or decrease in the number of shares of Common Stock effected without receipt of consideration by
the Company, the number of shares of Option Stock reserved under Section 6 hereof and the number of
shares of Option Stock covered by each outstanding option and the price per share thereof shall be
adjusted by the Board to reflect such change. Additional shares which may be credited pursuant to
such adjustment shall be subject to the same restrictions as are applicable to the shares with
respect to which the adjustment relates.
Unless otherwise provided in the stock option agreement, in the event of

     (i) an acquisition of the Company by a corporation, partnership, trust or other entity not
controlled by the Company through (A) the sale of substantially all of the Company’s assets and the
consequent discontinuance of its business or (B) through a merger, consolidation, exchange,
reorganization, reclassification, extraordinary dividend, divestiture or liquidation of the
Company, other than a merger or consolidation which would result in the voting securities of the
Company outstanding immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity) at least 80% of
the combined voting power of the voting securities of the Company or such surviving entity
outstanding immediately after such merger or consolidation (collectively referred to as a
“transaction”), or

     (ii) a change of control such that (A) any individual, partnership, trust or other entity
becomes after the effective date of the Plan the “beneficial owner” (as defined in Rule 13d-3 under
the Exchange Act), directly or indirectly, of 35% or more of the combined voting power of the
Company’s outstanding securities ordinarily having the right to vote at elections of directors of
the Company, or (B) individuals who constitute the Board of Directors of the Company on the
effective date of the Plan cease for any reason to constitute at least a majority thereof, provided
that any person becoming a director subsequent to the effective date of the Plan whose election, or
nomination for election by the Company’s shareholders, was approved by a vote of at least a
majority of the directors comprising the Board of Directors of the Company on the effective date of
the Plan (either by a specific vote or by approval of the proxy statement of the Company in which
such person is named as a nominee for director, without objection to such nomination) shall be, for
purposes of this clause (B) considered as though such person were a member of the Board of
Directors of the Company on the effective date of the Plan ((A) and (B) collectively with the
transactions described in (i) above referred to as “change of control transactions”),
all outstanding options shall become immediately exercisable, whether or not such options had
become exercisable prior to the change of control transaction; provided, however, that if the
acquiring party seeks to have the transaction accounted for on a “pooling of interests” basis and,
in the opinion of the Company’s independent certified public accountants, accelerating the
exercisability of such options would preclude a pooling of interests under generally accepted
accounting principles, the exercisability of such options shall not accelerate. In addition to the
foregoing, in the event of such a change of control transaction, the Board may provide for one or
more of the following:

     (a) the complete termination of this Plan and cancellation of outstanding options not
exercised prior to a date specified by the Board (which date shall give Optionees a
reasonable period of time in which to exercise the options prior to the effectiveness of
such change of control transaction);

     (b) that Optionees holding outstanding incentive or nonqualified options shall
receive, with respect to each share of Option Stock subject to such options, as of the
effective date

6

 

of any such change of control transaction, cash in an amount equal to the
excess of the Fair Market Value of such Option Stock on the date immediately preceding the
effective date of such change of control transaction over the option price per share of
such options; provided that the Board may, in lieu of such cash payment, distribute to such
Optionees shares of stock of the Company or shares of stock of any corporation succeeding
the Company by reason of such change of control transaction, such shares having a value
equal to the cash payment herein; or

     (c) the continuance of the Plan with respect to the exercise of options which were
outstanding as of the date of adoption by the Board of such plan for such change of control
transaction and provide to Optionees holding such options the right to exercise their
respective options as to an equivalent number of shares of stock of the corporation
succeeding the Company by reason of such transaction.

The Board may restrict the rights of or the applicability of this Section 12 to the extent
necessary to comply with Section 16(b) of the Securities Exchange Act of 1934, the Internal Revenue
Code or any other applicable law or regulation. The grant of an option pursuant to the Plan shall
not limit in any way the right or power of the Company to make adjustments, reclassifications,
reorganizations or changes of its capital or business structure or to merge, exchange or
consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets.

SECTION 13.

SECURITIES LAW COMPLIANCE

     No shares of Common Stock shall be issued pursuant to the Plan unless and until there has been
compliance, in the opinion of Company’s counsel, with all applicable legal requirements, including
without limitation, those relating to securities laws and stock exchange listing requirements. As
a condition to the issuance of Option Stock to Optionee, the Administrator may require Optionee to
(i) represent that the shares of Option Stock are being acquired for investment and not resale and
to make such other representations as the Administrator shall deem necessary or appropriate to
qualify the issuance of the shares as exempt from the Securities Act of 1933 and any other
applicable securities laws, and (ii) represent that Optionee shall not dispose of the shares of
Option Stock in violation of the Securities Act of 1933 or any other applicable securities laws.

     As a further condition to the grant of any incentive or nonqualified stock option or the
issuance of Option Stock to Optionee, Optionee agrees to the following:

     (a) In the event the Company advises Optionee that it plans an underwritten public offering of
its Common Stock in compliance with the Securities Act of 1933, as amended, and the underwriter(s)
seek to impose restrictions under which certain shareholders may not sell or contract to sell or
grant any option to buy or otherwise dispose of part or all of their stock purchase rights of the
underlying Common Stock, Optionee will not, for a period not to exceed 180 days from the
prospectus, sell or contract to sell or grant an option to buy or otherwise dispose of any
incentive or nonqualified stock option granted to Optionee pursuant to the Plan or any of the
underlying shares of Common Stock without the prior written consent of the underwriter(s) or its
representative(s).

     (b) In the event the Company makes any public offering of its securities and determines in its
sole discretion that it is necessary to reduce the number of issued but unexercised stock purchase
rights so as to comply with any states securities or Blue Sky law limitations with respect thereto,
the Board of Directors of the Company shall have the right (i) to accelerate the exercisability of
any incentive or nonqualified stock option and the date on which such option must be exercised,
provided that the Company gives Optionee prior written notice of such acceleration, and (ii) to
cancel any options or portions thereof which Optionee does not exercise prior to or
contemporaneously with such public offering.

     (c) In the event of a transaction (as defined in Section 12 of the Plan) which is treated as a
“pooling of interests” under generally accepted accounting principles, Optionee will comply with
Rule 145

7

 

of the Securities Act of 1933 and any other restrictions imposed under other applicable
legal or accounting principles if Optionee is an “affiliate” (as defined in such applicable legal
and accounting principles) at the time of the transaction, and Optionee will execute any documents
necessary to ensure compliance with such rules.

     The Company reserves the right to place a legend on any stock certificate issued upon exercise
of an option granted pursuant to the Plan to assure compliance with this Section 14.

SECTION 14.

RIGHTS AS A SHAREHOLDER

     An Optionee (or the Optionee’s successor or successors) shall have no rights as a shareholder
with respect to any shares covered by an option until the date of the issuance of a stock
certificate evidencing such shares. No adjustment shall be made for dividends (ordinary or
extraordinary, whether in cash, securities or other property), distributions or other rights for
which the record date is prior to the date such stock certificate is actually issued (except as
otherwise provided in Section 12 of the Plan).

SECTION 15.

AMENDMENT OF THE PLAN

     The Board may from time to time, insofar as permitted by law, suspend or discontinue the Plan
or revise or amend it in any respect; provided, however, that no such revision or amendment, except
as is authorized in Section 12, shall impair the terms and conditions of any option which is
outstanding on the date of such revision or amendment to the material detriment of the Optionee
without the consent of the Optionee. Notwithstanding the foregoing, no such revision or amendment
shall (i) materially increase the number of shares subject to the Plan except as provided in
Section 12 hereof, (ii) change the designation of the class of employees eligible to receive
options, (iii) decrease the price at which options may be granted, or (iv) materially increase the
benefits accruing to Optionees under the Plan without the approval of the shareholders of the
Company if such approval is required for compliance with the requirements of any applicable law or
regulation. Furthermore, the Plan may not, without the approval of the shareholders, be amended in
any manner that will cause incentive stock options to fail to meet the requirements of Section 422
of the Internal Revenue Code.

SECTION 16.

NO OBLIGATION TO EXERCISE OPTION

     The granting of an option shall impose no obligation upon the Optionee to exercise such
option. Further, the granting of an option hereunder shall not impose upon the Company or any
Subsidiary any obligation to retain the Optionee in its employ for any period.

SECTION 17.

GRANTING OF OPTIONS TO NON-EMPLOYEE DIRECTORS

     (a) Initial Grant. Each Non-Employee Director of the Company whose initial election or
appointment to the Board of Directors occurs on or after the date this Plan is approved by the
Company’s shareholders shall, as of the date of such election, automatically be granted an option
to purchase twenty-five thousand (25,000) shares of the Common Stock at an option price per share
equal to 100% of the Fair Market Value of the Common Stock on such date. Options granted pursuant
to this subsection (a) shall be immediately exercisable to the extent of twenty five percent (25%)
shares subject to such option and to the extent of an additional twenty five percent (25%) shares
on each of the first three anniversary dates of the date of grant.

8

 

     (b) Annual Grant. On March 1 of each year following the date this Plan is approved by the
Company’s shareholders, each Non Employee Director shall automatically be granted an option to
purchase five thousand (5,000) shares of the Common Stock at an option price per share equal to
100% of the Fair Market Value of the Common Stock on the date of grant. Options granted pursuant
to this subsection (b) shall become exercisable in full on the first anniversary date of the date
of grant.

     (c) General. All options granted pursuant to this Section 17 shall be designated as
nonqualified options and shall be subject to the same terms and provisions as are then in effect
with respect to granting of nonqualified options to officers and employees of the Company except
that the option shall expire on the earlier of (i) one year after the Optionee ceases to be a
director for any reason and (ii) ten (10) years after the date of grant.

9exv10w1

Exhibit 10.1

SUBSCRIPTION AGREEMENT

Columbia Laboratories, Inc.

354 Eisenhower Parkway

Livingston, New Jersey 07039

Gentlemen:

The undersigned (the “Investor”) hereby confirms its agreement with you as follows:

     1. This Subscription Agreement, including the Terms and Conditions For Purchase of Units
attached hereto as Annex I (this “Agreement”), is made as of the date set forth below between
Columbia Laboratories, Inc., a Delaware corporation (the “Company”), and the Investor.

     2. The Company has authorized the sale and issuance to certain investors of up to an aggregate
of 10,900,000 units (the “Units”), each consisting of (i) one share (the “Share,” and collectively,
the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), and (ii) one
warrant (the “Warrant,” and collectively, the “Warrants”) to purchase 0.5 shares of Common Stock
(and the fractional amount being the “Warrant Ratio”), in substantially the form attached hereto as
Exhibit B, subject to adjustment by the Company’s Board of Directors, or a committee
thereof, for a purchase price of $1.08 per Unit (the “Purchase Price”). The Shares issuable upon
exercise of the Warrants are referred to herein as the “Warrant Shares” and, together with the
Units, the Shares and the Warrants, are referred to herein as the “Securities.”

     3. The offering and sale of the Units (the “Offering”) are being made pursuant to (1) an
effective Registration Statement on Form S-3 (including the prospectus contained therein (the “Base
Prospectus”), the “Registration Statement”) filed by the Company with the Securities and Exchange
Commission (the “Commission”), (2) if applicable, certain “free writing prospectuses” (as that term
is defined in Rule 405 under the Securities Act of 1933, as amended (the “Act”)), that have been or
will be filed with the Commission and delivered to the Investor on or prior to the date hereof and
(3) a Prospectus Supplement (the “Prospectus Supplement” and together with the Base Prospectus, the
“Prospectus”) containing certain supplemental information regarding the Securities and terms of the
Offering that will be filed with the Commission and delivered to the Investor (or made available to
the Investor by the filing by the Company of an electronic version thereof with the Commission).

     4. The Company and the Investor agree that the Investor will purchase from the Company and the
Company will issue and sell to the Investor the Units set forth below for the aggregate purchase
price set forth below. The Units shall be purchased pursuant to the Terms and Conditions for
Purchase of Units attached hereto as Annex I and incorporated herein by this reference as
if fully set forth herein. The Investor acknowledges that the Offering is not being underwritten
by the placement agents (the “Placement Agents”) named in the Prospectus Supplement and that there
is no minimum offering amount.

     5. The manner of settlement of the Shares included in the Units purchased by the Investor
shall be determined by such Investor by delivery versus payment (“DVP”) through The Depository
Trust Company (“DTC”) (i.e., the Company shall issue Shares registered in the Investor’s name and
address as set forth below and released by American Stock Transfer and Trust Company, LLC, the
Company’s transfer agent (the “Transfer Agent”) to the Investor through DTC at the Closing directly
to the account(s) at Oppenheimer & Co. Inc. (“Oppenheimer”) identified by the Investor and
simultaneously therewith payment shall be made by Oppenheimer by wire transfer to the Company). NO
LATER THAN ONE (1) BUSINESS DAY AFTER THE EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE
COMPANY, THE INVESTOR SHALL:

 

 

	 	(I)	 	NOTIFY OPPENHEIMER OF THE ACCOUNT OR ACCOUNTS AT OPPENHEIMER TO BE
CREDITED WITH THE SHARES BEING PURCHASED BY SUCH INVESTOR, AND
	 
	 	(II)	 	CONFIRM THAT THE ACCOUNT OR ACCOUNTS AT OPPENHEIMER TO BE CREDITED WITH
THE SHARES BEING PURCHASED BY THE INVESTOR HAVE A MINIMUM BALANCE EQUAL TO THE
AGGREGATE PURCHASE PRICE FOR THE UNITS BEING PURCHASED BY THE INVESTOR.

IT IS THE INVESTOR’S RESPONSIBILITY TO (A) MAKE THE NECESSARY WIRE TRANSFER OR CONFIRM THE
PROPER ACCOUNT BALANCE IN A TIMELY MANNER AND (B) ARRANGE FOR SETTLEMENT BY WAY OF THE
DEPOSIT/WITHDRAWAL AT CUSTODIAN (“DWAC”) SYSTEM OR DVP IN A TIMELY MANNER. IF THE INVESTOR DOES
NOT DELIVER THE AGGREGATE PURCHASE PRICE FOR THE UNITS OR DOES NOT MAKE PROPER ARRANGEMENTS FOR
SETTLEMENT IN A TIMELY MANNER, THE SHARES AND WARRANTS MAY NOT BE DELIVERED AT CLOSING TO THE
INVESTOR OR THE INVESTOR MAY BE EXCLUDED FROM THE OFFERING ALTOGETHER.

     6. The executed Warrant shall be delivered in accordance with the terms thereof.

     7. The Investor represents that, except as set forth below, (a) it has had no position, office
or other material relationship within the past three years with the Company or persons known to it
to be affiliates of the Company, (b) it is not a FINRA member or an Associated Person (as such term
is defined under the FINRA Membership and Registration Rules Section 1011) as of the Closing, and
(c) neither the Investor nor any group of Investors (as identified in a public filing made with the
Commission) of which the Investor is a part in connection with the Offering, acquired, or obtained
the right to acquire, 20% or more of the Common Stock (or securities convertible into or
exercisable for Common Stock) or the voting power of the Company on a post-transaction basis.
Exceptions:

 
(If no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

     8. The Investor represents that it has received (or otherwise had made available to it by the
filing by the Company of an electronic version thereof with the Commission) the Base Prospectus,
dated December 5, 2008, which is a part of the Company’s Registration Statement, the documents
incorporated by reference therein and any free writing prospectus (collectively, the “Disclosure
Package”), prior to or in connection with the receipt of this Agreement. The Investor acknowledges
that, prior to the delivery of this Agreement to the Company, the Investor will receive certain
additional information regarding the Offering, including pricing information (the “Offering
Information”). Such information may be provided to the Investor by any means permitted under the
Act, including the Prospectus Supplement, a free writing prospectus and oral communications.

     9. No offer by the Investor to buy Units will be accepted and no part of the Purchase Price
will be delivered to the Company until the Investor has received the Offering Information and the
Company has accepted such offer by countersigning a copy of this Agreement, and any such offer may
be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the
Company (or a Placement Agent on behalf of the Company) sending (orally, in writing or by
electronic mail) notice of its acceptance of such offer. An indication of interest will involve no
obligation or commitment of any kind until the Investor has been delivered the Offering Information
and this Agreement is accepted and countersigned by or on behalf of the Company.

Number of Units:                                         

-2-

 

Purchase Price Per Unit: $1.08

Aggregate Purchase Price: $                                        

     Please confirm that the foregoing correctly sets forth the agreement between us by signing in
the space provided below for that purpose.

	 	 	 	 	 
	 

	 	Dated as of: October ___, 2009

	 	 
	 

	 	 

	 	 
	 

	 	INVESTOR	 	 

	 
	 

	 	By:  

	 	 
	 

	 	Print Name: 

	 	 
	 

	 	Title: 

	 	 
	 

	 	Address: 
	 	 
	 

	 	 

	 	 

	 	 	 	 	 
	Agreed and Accepted 

this ___ day of October, 2009:

COLUMBIA LABORATORIES, INC.

 	 
	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 

-3-

 

	 	 	 	 	 

ANNEX I

TERMS AND CONDITIONS FOR PURCHASE OF UNITS

     1. Authorization and Sale of the Units. Subject to the terms and conditions of this
Agreement, the Company has authorized the sale of the Units.

     2. Agreement to Sell and Purchase the Units; Placement Agents.

          2.1 At the Closing (as defined in Section 3.1), the Company will sell to the Investor,
and the Investor will purchase from the Company, upon the terms and conditions set forth herein,
the number of Units set forth on the last page of the Agreement to which these Terms and Conditions
for Purchase of Units are attached as Annex I (the “Signature Page”) for the aggregate
purchase price therefor set forth on the Signature Page.

          2.2 The Company proposes to enter into substantially this same form of Subscription Agreement
with certain other investors (the “Other Investors”) and expects to complete sales of Units to
them. The Investor and the Other Investors are hereinafter sometimes collectively referred to as
the “Investors,” and this Agreement and the Subscription Agreements executed by the Other Investors
are hereinafter sometimes collectively referred to as the “Agreements.”

          2.3 Investor acknowledges that the Company has agreed to pay Oppenheimer & Co. Inc. and The
Benchmark Company, LLC (the “Placement Agents”) a fee (the “Placement Fee”) in respect of the sale
of Units to the Investor.

          2.4 The Company has entered into a Placement Agent Agreement, dated October 22, 2009, (the
“Placement Agreement”), with the Placement Agents that contains certain representations,
warranties, covenants and agreements of the Company that may be relied upon by the Investor, which
shall be a third party beneficiary thereof. The Company represents and warrants that a true and
correct copy of the Placement Agreement is attached hereto as Exhibit C and the Company
confirms that all references in the Placement Agreement to “Purchasers” shall include the Investor
and Other Investors. The Company shall promptly notify the Investor of any proposed amendment or
modification to Section 3 (Representations and Warranties of the Company), Section 5 (Further
Agreements of the Company), Section 7 (Conditions to the Obligations of the Placement Agent and the
Purchasers, and the Sale of the Shares), Section 9 (Termination), Section 12 (Successors; Persons
Entitled to Benefit of Agreement) and Section 13 (Survival of Indemnities, Representations,
Warranties, etc.) of the Placement Agreement, which shall require the prior written consent of the
Investor.

          2.5 The Company acknowledges that the only material, non-public information relating to the
Company or its subsidiaries that the Company, its employees or agents has provided to the Investor
in connection with the Offering prior to the date hereof is the existence of the Offering. The
Company confirms that neither it nor any other Person acting on its behalf has provided the
Investor or their agents or counsel with any information, other than information relating to the
Offering, that constitutes or could reasonably be expected to constitute material, nonpublic
information, except as will be disclosed in the Prospectus and the Company’s Form 8-K to be filed
with the Commission in connection with the Offering. The Company understands and confirms that the
Investor will rely on the foregoing representations in effecting transactions in securities of the
Company.

     3. Closings and Delivery of the Units and Funds.

          3.1 Closing. The completion of the purchase and sale of the Units (the “Closing”)
shall occur at a place and time (the “Closing Date”) to be specified by the Company and the
Placement Agents, and of which the Investors will be notified in advance by the Placement Agents,
in accordance with Rule 15c6-1

-4-

 

promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). At
the Closing, (a) the Company shall cause the Transfer Agent to deliver to the Investor the number
of Shares set forth on the Signature Page registered in the name of the Investor or, if so
indicated on the Investor Questionnaire attached hereto as Exhibit A, in the name of a
nominee designated by the Investor, (b) the Company shall cause to be delivered to the Investor a
Warrant to purchase a number of whole Warrant Shares determined by multiplying the number of Shares
(and Units) set forth on the signature page by the Warrant Ratio and rounding down to the nearest
whole number and (c) the aggregate purchase price for the Units being purchased by the Investor
will be delivered by or on behalf of the Investor to the Company.

          3.2 Conditions to the Company’s Obligations. (a) The Company’s obligation to issue
and sell the Units to the Investor shall be subject to: (i) the receipt by the Company of the
purchase price for the Units being purchased hereunder as set forth on the Signature Page and (ii)
the accuracy of the representations and warranties made by the Investor and the fulfillment of
those undertakings of the Investor to be fulfilled prior to the Closing Date.

               (b) Conditions to the Investor’s Obligations. The Investor’s obligation to purchase
the Units will be subject to (i) the delivery by the Company of the Units in accordance with the
provisions of this Agreement, (ii) the accuracy of the representations and warranties made by the
Company and the fulfillment of those undertakings of the Company to be fulfilled prior to the
Closing Date, including without limitation, those contained in the Placement Agreement, and (iii)
the condition that the Placement Agents shall not have: (x) terminated the Placement Agreement
pursuant to the terms thereof or (y) determined that the conditions to the closing in the Placement
Agreement have not been satisfied. The Investor’s obligations are expressly not conditioned on the
purchase by any or all of the Other Investors of the Units that they have agreed to purchase from
the Company. The Investor understands and agrees that, in the event that the Placement Agents in
their sole discretion determine that the conditions to closing in the Placement Agreement have not
been satisfied or if the Placement Agreement may be terminated for any other reason permitted by
such Agreement, then the Placement Agents may, but shall not be obligated to, terminate such
Placement Agreement, which shall have the effect of terminating this Subscription Agreement
pursuant to Section 14 below.

          3.3 Delivery of Funds.

               (a) DWAC Delivery. If the Investor elects to settle the Shares purchased by such
Investor through DTC’s Deposit/Withdrawal at Custodian (“DWAC”) delivery system, no later than
one (1) business day after the execution of this Agreement by the Investor and the Company, the
Investor shall remit by wire transfer the amount of funds equal to the aggregate purchase price for
the Units being purchased by the Investor to the following account designated by the Company and
the Placement Agents pursuant to the terms of that certain Escrow Agreement (the “Escrow
Agreement”), dated as of October 22, 2009, by and among the Company, the Placement Agents and U.S.
Bank National Association (the “Escrow Agent”):

U.S. Bank National Association

ABA # [•]

Account Name: Columbia Laboratories, Inc.

Account Number: [•]

               Such funds shall be held in escrow until the Closing and delivered by the Escrow Agent on
behalf of the Investors to the Company upon the satisfaction, in the sole judgment of the Placement
Agents, of the conditions set forth in Section 3.2(b) hereof. The Placement Agents shall
have no rights in or to any of the escrowed funds, unless the Placement Agents and the Escrow Agent
are notified in writing by the Company in connection with the Closing that a portion of the
escrowed funds shall be applied to the Placement Fee. The Company and the Investor agree to
indemnify and hold the Escrow Agent harmless from and against any and all losses, costs, damages,
expenses and claims (including, without limitation, court costs and reasonable attorneys fees)
(“Losses”) arising under this Section 3.3 or otherwise with respect to the funds held in
escrow pursuant hereto or

-5-

 

arising under the Escrow Agreement, unless it is finally determined that such Losses resulted
directly from the willful misconduct or gross negligence of the Escrow Agent. Anything in this
Agreement to the contrary notwithstanding, in no event shall the Escrow Agent be liable for any
special, indirect or consequential loss or damage of any kind whatsoever (including but not limited
to lost profits), even if the Escrow Agent has been advised of the likelihood of such loss or
damage and regardless of the form of action.

               (b) Delivery Versus Payment through The Depository Trust Company. If the Investor
elects to settle the Shares purchased by such Investor by delivery versus payment through DTC,
no later than one (1) business day after the execution of this Agreement by the Investor and
the Company, the Investor shall confirm that the account or accounts at Oppenheimer to be
credited with the Units being purchased by the Investor have a minimum balance equal to the
aggregate purchase price for the Units being purchased by the Investor.

          3.4 Delivery of Shares.

               (a) DWAC Delivery. If the Investor elects to settle the Shares purchased by such
Investor through DTC’s DWAC delivery system, no later than one (1) business day after the
execution of this Agreement by the Investor and the Company, the Investor shall direct the
broker-dealer at which the account or accounts to be credited with the Shares being purchased by
such Investor are maintained, which broker/dealer shall be a DTC participant, to set up a DWAC
instructing the Transfer Agent to credit such account or accounts with the Shares. Such DWAC
instruction shall indicate the settlement date for the deposit of the Shares, which date shall be
provided to the Investor by Oppenheimer. Simultaneously with the delivery to the Company by the
Escrow Agent of the funds held in escrow pursuant to Section 3.3 above, the Company shall
direct the Transfer Agent to credit the Investor’s account or accounts with the Shares pursuant to
the information contained in the DWAC.

               (b) Delivery Versus Payment through The Depository Trust Company. If the Investor
elects to settle the Shares purchased by such Investor by delivery versus payment through DTC,
no later than one (1) business day after the execution of this Agreement by the Investor and
the Company, the Investor shall notify the Placement Agents of the account or accounts at the
Placement Agents to be credited with the Shares being purchased by such Investor. On the Closing
Date, the Company shall deliver the Shares to the Investor through DTC directly to the account(s)
at Oppenheimer & Co. Inc. identified by the Investor and simultaneously therewith payment shall be
made by the Placement Agents by wire transfer to the Company.

     4. Representations, Warranties and Covenants of the Investor.

     The Investor acknowledges, represents and warrants to, and agrees with, the Company and the
Placement Agents that:

          4.1 The Investor (a) is knowledgeable, sophisticated and experienced in making, and is
qualified to make decisions with respect to, investments in shares presenting an investment
decision like that involved in the purchase of the Units, including investments in securities
issued by the Company and investments in comparable companies, (b) has answered all questions on
the Signature Page and the Investor Questionnaire and the answers thereto are true and correct as
of the date hereof and will be true and correct as of the Closing Date and (c) in connection with
its decision to purchase the number of Units set forth on the Signature Page, has received and is
relying only upon the Disclosure Package and the documents incorporated by reference therein.

          4.2 (a) No action has been or will be taken in any jurisdiction outside the United States by
the Company or the Placement Agents that would permit an offering of the Units, or possession or
distribution of offering materials in connection with the issue of the Securities in any
jurisdiction outside the United States where action for that purpose is required, (b) if the
Investor is outside the United States, it will comply with all applicable laws and regulations in
each foreign jurisdiction in which it purchases, offers, sells or delivers Securities or has in its
possession or distributes any offering material, in all cases at its own expense and (c) the

-6-

 

Placement Agents are not authorized to make and have not made any representation, disclosure
or use of any information in connection with the issue, placement, purchase and sale of the Units,
except as set forth or incorporated by reference in the Base Prospectus or the Prospectus
Supplement.

          4.3 (a) The Investor has full right, power, authority and capacity to enter into this
Agreement and to consummate the transactions contemplated hereby and has taken all necessary action
to authorize the execution, delivery and performance of this Agreement, and (b) this Agreement
constitutes a valid and binding obligation of the Investor enforceable against the Investor in
accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting
parties’ rights generally and except as enforceability may be subject to general principles of
equity (regardless of whether such enforceability is considered in a proceeding in equity or at
law) and except as to the enforceability of any rights to indemnification or contribution that may
be violative of the public policy underlying any law, rule or regulation (including any federal or
state securities law, rule or regulation).

          4.4 The Investor understands that nothing in this Agreement, the Prospectus or any other
materials presented to the Investor in connection with the purchase and sale of the Units
constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or appropriate in
connection with its purchase of Units.

          4.5 Since the date on which the Placement Agents first contacted such Investor about the
Offering, the Investor has not engaged in any transactions in the securities of the Company
(including, without limitation, any Short Sales involving the Company’s securities). Each Investor
covenants that it will not engage in any transactions in the securities of the Company (including
Short Sales) prior to the time that the transactions contemplated by this Agreement are publicly
disclosed. The Investor agrees that it will not use any of the Units acquired pursuant to this
Agreement to cover any short position in the Common Stock if doing so would be in violation of
applicable securities laws. For purposes hereof, “Short Sales” include, without limitation, all
“short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act,
whether or not against the box, and all types of direct and indirect stock pledges, forward sales
contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule
16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and
sales and other transactions through non-U.S. broker dealers or foreign regulated brokers.

     5. Survival of Representations, Warranties and Agreements; Third Party Beneficiary.
Notwithstanding any investigation made by any party to this Agreement or by the Placement Agents,
all covenants, agreements, representations and warranties made by the Company and the Investor
herein will survive the execution of this Agreement, the delivery to the Investor of the Units
being purchased and the payment therefor. The Placement Agents shall be third party beneficiaries
with respect to the representations, warranties and agreements of the Investor in Section 4
hereof.

     6. Notices. All notices, requests, consents and other communications hereunder will be in
writing, will be mailed (a) if within the domestic United States by first-class registered or
certified airmail, or nationally recognized overnight express courier, postage prepaid, or by
facsimile or (b) if delivered from outside the United States, by International Federal Express or
facsimile, and will be deemed given (i) if delivered by first-class registered or certified mail
domestic, three business days after so mailed, (ii) if delivered by nationally recognized overnight
carrier, one business day after so mailed, (iii) if delivered by International Federal Express, two
business days after so mailed and (iv) if delivered by facsimile, upon electric confirmation of
receipt and will be delivered and addressed as follows:

          (a) if to the Company, to:

Columbia Laboratories, Inc.

354 Eisenhower Parkway

-7-

 

Livingston, New Jersey 07039

Attention: Senior Vice President, General Counsel and

Secretary

Facsimile: (973) 994-3001

with a copy (which shall not constitute notice) to:

KAYE SCHOLER LLP

425 Park Avenue

New York, NY 10027

Attention: Adam Golden, Esq.

Facsimile: (212) 836-6573

          (b) if to the Investor, at its address on the Signature Page hereto, or at such
other address or addresses as may have been furnished to the Company in writing.

     7. Changes. This Agreement may not be modified or amended except pursuant to an instrument
in writing signed by the Company and the Investor.

     8. Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and will not be deemed to be part of this Agreement.

     9. Severability. In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions contained herein will not in any way be affected or impaired thereby.

     10. Governing Law. This Agreement will be governed by, and construed in accordance with,
the internal laws of the State of New York, without giving effect to the principles of
conflicts of law that would require the application of the laws of any other jurisdiction.
No legal proceeding may be commenced, prosecuted or continued in any court other than the
courts of the State of New York located in the City and County of New York or in the United
States District Court for the Southern District of New York, which courts shall have
jurisdiction over the adjudication of such matters, and the Company and the Investor each
hereby consent to the jurisdiction of such courts and personal service with respect thereto.
The Company and the Investor each hereby consents to personal jurisdiction, service and
venue in any court in which any legal proceeding arising out of or in any way relating to
this Agreement is brought by any third party against the Company or the Investor. The
Company and the Investor each hereby waive all right to trial by jury in any legal
proceeding (whether based upon contract, tort or otherwise) in any way arising out of or
relating to this Agreement. The Company and the Investor agree that a final judgment in any
such legal proceeding brought in any such court shall be conclusive and binding upon the
Company and the Investor and may be enforced in any other courts in the jurisdiction of
which the Company or the Investor is or may be subject, by suit upon such judgment.

     11. Counterparts. This Agreement may be executed in two or more counterparts, each of which
will constitute an original, but all of which, when taken together, will constitute but one
instrument, and will become effective when one or more counterparts have been signed by each
party hereto and delivered to the other parties. The Company and the Investor acknowledge
and agree that the Company shall deliver its counterpart to the Investor along with the
Prospectus Supplement (or the filing by the Company of an electronic version thereof with
the Commission).

     12. Confirmation of Sale. The Investor acknowledges and agrees that such Investor’s receipt
of the Company’s signed counterpart to this Agreement, together with the Prospectus
Supplement (or the filing by the Company of an electronic version thereof with the
Commission), shall constitute written confirmation of the Company’s sale of Units to such
Investor.

-8-

 

     13. Press Release and Form 8-K. The Company and the Investor agree that the Company shall
on the business day immediately following the date hereof (a) issue a press release
announcing the material terms and conditions of the Offering prior to the opening of the
financial markets in New York City and (b) file a current report on Form 8-K with the
Securities and Exchange Commission including, but not limited to, a form of this Agreement
as an exhibit thereto. From and after the issuance of such press release and Current Report
on Form 8-K, the Company shall have publicly disclosed all material, non-public information
delivered to the Investor by the Company, if any, or any of its officers or directors in
connection with the transactions contemplated hereby. The Company shall not identify any
Investor by name in any press release or public filing, or otherwise publicly disclose any
Investor’s name, without such Investor’s prior written consent, unless required by law or
the rules and regulations of a national securities exchange.

     14. Termination. In the event that the Placement Agreement is terminated by the Placement
Agents pursuant to the terms thereof, this Agreement shall terminate without any further
action on the part of the parties hereto.

-9-

 

Exhibit A

COLUMBIA LABORATORIES, INC.

INVESTOR QUESTIONNAIRE

     Pursuant to Section 3 of Annex I to the Agreement, please provide us with the
following information:

	 	 	 	 	 
	1. The exact name that your Shares and Warrants are to be registered
in. You may use a nominee name if appropriate:
	 	 	 	 
	 
	 	 	 
	 
	2. The relationship between the Investor and the registered holder
listed in response to item 1 above:
	 	 	 	 
	 
	 	 	 
	 
	3. The mailing address of the registered holder listed in response to
item 1 above:
	 	 	 	 
	 
	 	 	 
	 
	4. The Social Security Number or Tax Identification Number of the
registered holder listed in the response to item 1 above:
	 	 	 	 
	 
	 	 	 
	 
	5. Name of DTC Participant (broker-dealer at which the account or
accounts to be credited with the Shares are maintained):
	 	 	 	 
	 
	 	 	 
	 
	6. DTC Participant Number:
	 	 	 	 
	 
	 	 	 
	 
	7. Name of Account at DTC Participant being credited with the Shares:
	 	 	 	 
	 
	 	 	 
	 
	8. Account Number at DTC Participant being credited with the Shares:
	 	 	 	 
	 
	 	 	 

 

 

Exhibit B

Form of Warrant

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]